You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
429 Long-term analysis of MASTERKEY-265 phase 1b trial of talimogene laherparepvec (T-VEC) plus pembrolizumab in patients with unresectable stage IIIB-IVM1c melanoma

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020347031
Dec 20204006
Jan 202190010
Feb 2021373040
Mar 2021272043
Apr 2021322031
May 2021136032
Jun 20210027
Jul 20210023
Aug 20210031
Sep 20210026
Oct 2021188054
Nov 2021199040
Dec 2021118015
Jan 2022242028
Feb 2022184026
Mar 2022212030
Apr 2022222030
May 2022174030
Jun 2022186021
Jul 20228806
Aug 2022136018
Sep 2022458024
Oct 2022166013
Nov 2022222015
Dec 202210609
Jan 2023136012
Feb 2023230025
Mar 2023124011
Apr 202388021
May 2023162026
Jun 202398015
Jul 2023166039
Aug 2023134024
Sep 20238609
Oct 202310208
Nov 2023164015
Dec 202313607
Jan 20243802
Feb 20246803
Mar 2024110012
Apr 2024120015
May 202490014
Jun 202487011
Jul 20249604
Aug 202410606
Sep 202484010
Oct 202414409
Nov 202492012
Dec 2024236024
Jan 2025114015
Feb 202518010
Mar 20250017
Apr 20250017
May 20250018
Jun 20250015
Total751001085